(:BDSI)

Apr 27, 2022 07:30 am ET
Genenta Announces Nomination of Mark A. Sirgo as Chair
Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over...
Mar 22, 2022 05:01 pm ET
Collegium Completes the Acquisition of BDSI
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to build...
Mar 01, 2022 01:50 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates SJI, OBNK, CTXS, BDSI
NEW YORK, March 1, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 24, 2022 08:30 am ET
BioDelivery Sciences International Announces ELYXYB™ is Now Available in the U.S. for the Acute Treatment of Migraine
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced the U.S. commercial launch and availability of ELYXYBTM...
Feb 22, 2022 04:20 pm ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FLOW, BDSI, CHWA, DNAA, CCMP
NEW YORK, Feb. 22, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 16, 2022 09:50 pm ET
BIODELIVERY SCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of BioDelivery Sciences Internationa
NEW ORLEANS, Feb. 16, 2022 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed sale of BioDelivery Sciences International, Inc. (NasdaqGS: BDSI) to Collegium Pharmaceutical, Inc. (NasdaqGS: COLL). Under the terms of the proposed transaction, shareholders of BioDelivery will receive only $5.60 in cash for each share of BioDelivery that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration underval
Feb 16, 2022 10:35 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BDSI, ZWS, TSEM, MGI
Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: BioDelivery Sciences International,...
Feb 15, 2022 05:47 pm ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery Sciences International, Inc. (Nasdaq - BDSI), Zurn Water Solutions Corporation (NYSE - ZWS), Edoc A
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky or Marc Ackerman at 855-576-4847. There is no cost or financial obligation to you. BioDelivery...
Feb 15, 2022 04:36 pm ET
Moore Kuehn Encourages BDSI, ZWS, EYES, and GIIX Investors to Contact Law Firm
NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders.  Moore Kuehn may seek increased consideration, additional disclosures, or other relief on behalf of the shareholders of these companies:
Feb 15, 2022 08:30 am ET
SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates BDSI, ZWS, NLIT, SPK, SWAG
NEW YORK, Feb. 15, 2022 /PRNewswire/ -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Feb 14, 2022 09:34 pm ET
Shareholder Alert: The M&A Class Action Firm is Investigating the Merger of BDSI, ZWS, RRD, QDEL, RC, TACO
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm rated Top 50 in the 2018-2020 ISS Securities Class Action Services Report and headquartered at the Empire State Building in New York City, is investigating:
Feb 14, 2022 12:20 pm ET
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) (“BDSI”) breached their fiduciary...
Feb 14, 2022 11:30 am ET
BDSI Stock Alert: Halper Sadeh LLP Is Investigating Whether the Sale of BioDelivery Sciences International, Inc. Is Fair to Shareholders
Halper Sadeh LLP, an investor rights law firm, is investigating whether the sale of BioDelivery Sciences International, Inc. (NASDAQ: BDSI) to Collegium Pharmaceutical, Inc. for $5.60 per share is fair to BioDelivery shareholders.
Feb 14, 2022 09:12 am ET
BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences International to Collegium Pharmaceutical
The law firm of Wohl & Fruchter LLP is investigating whether the directors of BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI”) acted in the best interests of BDSI shareholders in approving the sale of BDSI to Collegium...
Feb 14, 2022 08:48 am ET
Shareholder Alert: Ademi LLP investigates whether BioDelivery Sciences International, Inc. has obtained a Fair Price in its transaction with Collegium.
MILWAUKEE, Feb. 14, 2022 /PRNewswire/ -- Ademi LLP is investigating BioDelivery Sciences (NASDAQ: BDSI) for possible breaches of fiduciary duty and other violations of law in its transaction with Collegium. 
Feb 14, 2022 07:30 am ET
Thinking about buying stock in BioDelivery Sciences, China Online Education, Gold Fields, Y-mAbs Therapeutics, or Bloom Energy?
NEW YORK, Feb. 14, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BDSI, COE, GFI, YMAB, and BE.
Feb 14, 2022 06:30 am ET
Collegium to Acquire BioDelivery Sciences in an All-Cash Deal
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it has entered into a definitive merger agreement for...
Jan 20, 2022 08:00 am ET
BioDelivery Sciences Expects 2021 Revenue at the High End of Full Year Guidance
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced it expects 2021 total Company net revenues and BELBUCA®...
Dec 20, 2021 04:27 pm ET
BioDelivery Sciences Prevails in BELBUCA® ANDA Litigation Maintaining Patent Exclusivity Against Alvogen Until 2032
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that the U.S. District Court of Delaware has issued an...
Nov 03, 2021 08:00 am ET
BioDelivery Sciences Reports Solid Third Quarter 2021 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported solid financial results for the third quarter ended...
Oct 21, 2021 08:00 am ET
BioDelivery Sciences Appoints John Golubieski as Chief Financial Officer
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the appointment of John Golubieski as Chief Financial...
Oct 20, 2021 08:00 am ET
BioDelivery Sciences to Report Third Quarter 2021 Financial Results on November 3, 2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it will report its third quarter 2021 financial results before the open...
Sep 30, 2021 08:00 am ET
BioDelivery Sciences International to Host ELYXYB™ Investor Day
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today it will host a virtual ELYXYB™ Investor Day on Thursday, October 14, 2021, at...
Sep 09, 2021 08:30 am ET
BioDelivery Sciences International Completes Acquisition of ELYXYB™ for Acute Migraine Treatment in the U.S. and Canada
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced today that it has completed the acquisition of U.S. and Canadian rights to ELYXYB™...
Sep 07, 2021 09:28 am ET
BioDelivery Sciences to Exhibit Three Scientific Posters Comparing BELBUCA® to Oxycodone at the PAINWeek 2021 Conference
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will showcase three scientific posters regarding BELBUCA® (buprenorphine buccal film), CIII at...
Sep 03, 2021 08:00 am ET
BioDelivery Sciences to Participate in Upcoming Virtual Investor Conferences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and...
Aug 16, 2021 08:00 am ET
AzurRx BioPharma Announces Appointment of Terry Coelho to its Board of Directors
AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the appointment of Terry Coelho to its Board of...
Aug 04, 2021 08:00 am ET
BioDelivery Sciences Reports Second Quarter 2021 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter ended June...
Aug 04, 2021 07:30 am ET
BioDelivery Sciences Announces Agreement to Acquire U.S. and Canadian Rights to FDA-approved ELYXYB™ for the Acute Treatment of Migraine
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today that it entered into an agreement on August 3, 2021 with...
Jul 22, 2021 08:00 am ET
BioDelivery Sciences to Report Second Quarter 2021 Financial Results on August 4, 2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2021...
May 06, 2021 08:00 am ET
BioDelivery Sciences Reports First Quarter 2021 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the first quarter ended March...
Apr 20, 2021 08:00 am ET
BioDelivery Sciences to Report First Quarter 2021 Financial Results on May 6, 2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2021...
Mar 10, 2021 08:00 am ET
BioDelivery Sciences Reports Strong Q4 and Record Full-Year 2020 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the fourth quarter and...
Feb 17, 2021 08:00 am ET
BioDelivery Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on March 10, 2021
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full...
Feb 11, 2021 08:00 am ET
BioDelivery Sciences CFO Terry Coelho Promoted to Executive Vice President
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, promoted its Chief Financial Officer, Terry Coelho, to Executive Vice President and...
Feb 03, 2021 07:45 am ET
An Aging Population is Increasing the Need for Novel Treatments
NEW YORK, Feb. 3, 2021 /PRNewswire/ -- With the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population has tripled in size over the past 40 years. The elderly are at a higher risk of contracting diseases such as cancers, Parkinson's, diabetes, and arthritis, which has led to increased rates of these diseases. Fortunately, with the assistance of pharmaceutical companies, this vulnerable population can seek protection against such diseases. Pharmaceutical companies involved in products to help this aging populat
Jan 15, 2021 09:00 am ET
BioDelivery Sciences to Present Three Scientific Posters Comparing BELBUCA® to Oxycodone at the 2021 North American Neuromodulation Society (NANS) Meeting
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, will present three scientific posters regarding BELBUCA® (buprenorphine buccal film),...
Nov 20, 2020 08:30 am ET
BioDelivery Sciences to Participate in the Piper Sandler 32nd Annual Healthcare Conference
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeff Bailey, Chief Executive Officer, and...
Nov 11, 2020 08:30 am ET
BioDelivery Sciences to Present Virtually and Host 1x1 Investor Meetings at the Annual Southwest IDEAS Investor Conference on November 18
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Chief Executive Officer, and...
Nov 05, 2020 08:00 am ET
BioDelivery Sciences Reports Strong Q3 2020 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the third quarter...
Nov 04, 2020 05:31 pm ET
BioDelivery Sciences Announces $25 Million Share Repurchase Program
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has authorized the...
Nov 04, 2020 05:10 pm ET
BioDelivery Sciences Announces Appointment of Jeff Bailey as Permanent CEO
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that its Board of Directors has appointed Jeff...
Oct 23, 2020 08:00 am ET
BioDelivery Sciences to Report Third Quarter 2020 Financial Results on November 5, 2020
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its third quarter 2020...
Sep 11, 2020 08:00 am ET
BioDelivery Sciences Announces Five Scientific Poster Presentations at PAINWeek® 2020 National Conference on Pain Management
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced the presentation of five scientific posters highlighting data...
Sep 03, 2020 08:00 am ET
BioDelivery Sciences to Present at Two Upcoming Investor Conferences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Interim Chief Executive...
Aug 05, 2020 07:45 am ET
BioDelivery Sciences Reports Strong Q2 2020 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the second quarter...
Jul 27, 2020 04:01 pm ET
BioDelivery Sciences to Report Second Quarter 2020 Financial Results on August 5, 2020
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its second quarter 2020...
May 29, 2020 12:17 pm ET
BioDelivery Sciences to Present at Two Upcoming Investor Conferences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey, Interim Chief Executive...
May 11, 2020 08:30 am ET
BioDelivery Sciences Appoints Jeff Bailey Interim CEO
BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey A. Bailey, a member of the Company’s...
May 07, 2020 04:01 pm ET
BioDelivery Sciences Reports Strong Q1 2020 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the first quarter...
Apr 28, 2020 08:00 am ET
BioDelivery Sciences to Report First Quarter 2020 Financial Results on May 7, 2020
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its first quarter 2020...
Mar 12, 2020 04:01 pm ET
BioDelivery Sciences Reports Strong Fourth Quarter and Full-Year 2019 Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today reported strong financial results for the fourth quarter and...
Mar 09, 2020 08:00 am ET
BioDelivery Sciences Appoints Jeffrey A. Bailey to its Board of Directors
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it has appointed Jeffrey A. Bailey to its...
Feb 27, 2020 05:15 pm ET
BioDelivery Sciences Announces Phase I Clinical Trial Results at the American Academy of Pain Medicine’s 36th Annual Meeting
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today presented at the American Academy of Pain Medicine’s (AAPM)...
Feb 20, 2020 08:00 am ET
BioDelivery Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that it will report its fourth quarter and full...
Jan 13, 2020 08:30 am ET
BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that a large national pharmacy benefit manager...
Jan 06, 2020 08:30 am ET
BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development
BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced today the appointment of Kevin Ostrander as Senior Vice...
Dec 19, 2019 08:30 am ET
BioDelivery Sciences Added to NASDAQ Biotechnology Index
BioDelivery Sciences International, Inc. (Nasdaq: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced it has been selected for addition to the NASDAQ...
Nov 27, 2019 08:30 am ET
BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will...
Nov 25, 2019 08:30 am ET
BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that it has named Vanila M. Singh, M.D., MACM, to its...
Nov 12, 2019 04:01 pm ET
BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today reported strong financial results for the third quarter ended...
Nov 07, 2019 08:00 am ET
BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will...
Oct 30, 2019 08:00 am ET
BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its plans to report its third-quarter 2019 financial results after the close of the...
Oct 01, 2019 08:00 am ET
BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that a major PBM will begin providing improved patient access to BELBUCA®...
Sep 17, 2019 04:05 pm ET
BioDelivery Sciences Announces Participation in Upcoming Investor Conferences
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that Herm Cukier, Chief Executive Officer, will...
Aug 28, 2019 07:45 am ET
BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today reported the acceptance of five scientific abstracts highlighting data...
Aug 08, 2019 04:05 pm ET
BioDelivery Sciences Reports Strong Second Quarter 2019 Results and Raises Net Sales Expectations
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today reported strong financial results for the second quarter ended...
Jul 30, 2019 07:45 am ET
BioDelivery Sciences to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8, 2019
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its plans to report its second-quarter 2019 financial results after the close of the...
Jul 29, 2019 01:47 pm ET
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating BioDelivery Sciences International, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
NEW YORK, July 29, 2019 /PRNewswire/ -- Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of BioDelivery Sciences International, Inc. (NASDAQ: BDSI).
Jul 09, 2019 08:00 am ET
BioDelivery Sciences Announces Further Improved Insurance Coverage for BELBUCA®
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced that several regional health care plans improved patient access to BELBUCA®...
Jun 24, 2019 08:00 am ET
BioDelivery Sciences Expands Upon Report from Pain Management Task Force
BioDelivery Sciences International, Inc. (Nasdaq: BDSI), the manufacturer of BELBUCA® (buprenorphine buccal film), CIII, shared today how its scientific investments for BELBUCA throughout 2019, including clinical trials, publications, and medical...
Jun 20, 2019 08:00 am ET
BioDelivery Sciences Named to the Russell 3000® Index
BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is set to be added to the broad-market Russell 3000® Index as well as the Russell 2000® Index at the conclusion of the 2019 Russell indexes annual reconstitution, effective July 1, 2019,...
May 29, 2019 04:10 pm ET
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions today announced that Herm Cukier, Chief Executive Officer will present...
May 28, 2019 04:10 pm ET
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI”) today announced that it has successfully completed the refinancing of its existing debt agreement with a new facility from BioPharma Credit plc (“BPCR”). The new facility consists of...
May 06, 2019 04:05 pm ET
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic conditions, today reported strong financial results for the first quarter ended...
Apr 25, 2019 04:30 pm ET
BioDelivery Sciences to Report First Quarter 2019 Financial Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its first quarter 2019 financial...
Apr 16, 2019 07:15 am ET
New Research: Key Drivers of Growth for Teradyne, Lazard, Graphic Packaging Holding, Natus Medical, Flotek Industries, and BioDelivery Sciences International — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Teradyne, Inc. (NASDAQ:TER), Lazard Ltd (NYSE:LAZ), Graphic Packaging...
Apr 11, 2019 09:29 am ET
BioDelivery Sciences International, Inc. Announces Pricing of Public Offering of Common Stock
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced the pricing of an underwritten public offering by the Company and a selling stockholder of 12,000,000 shares of common stock at a public offering...
Apr 10, 2019 04:07 pm ET
BioDelivery Sciences International, Inc. Announces Proposed Underwritten Public Offering of Common Stock
BioDelivery Sciences International, Inc. (Nasdaq: BDSI) (“BDSI” or the “Company”) today announced that it is commencing an underwritten public offering of shares of common stock. In addition, the underwriters will have a 30-day option to purchase...
Apr 10, 2019 04:06 pm ET
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it has entered into an exclusive licensing agreement...
Mar 14, 2019 04:05 pm ET
BioDelivery Sciences Reports Strong 2018 Results and 2019 Expectations
BELBUCA® prescription growth further accelerated to an all-time high during the fourth quarterCompany increases Belbuca 2019 net sales expectations to $80-$85 millionOperating cash flow to become positive in 2019 Long-term potential for BELBUCA net sales believed to be $250 - $300 million
Mar 12, 2019 10:58 am ET
BioDelivery Sciences Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether BioDelivery Sciences International, Inc. (“BioDelivery Sciences” or the “Company”) (NASDAQ: BDSI) and certain of its...
Feb 21, 2019 07:45 am ET
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its fourth quarter and full year 2018...
Feb 19, 2019 07:20 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Procter & Gamble, Hertz Global, NN, Omnicell, BioDelivery Sciences International, and Movado Group — New Research Emphasizes Economi
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Procter & Gamble Company (NYSE:PG), Hertz Global Holdings, Inc (NYSE:HTZ),...
Feb 04, 2019 08:03 am ET
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that a leading national managed care organization has moved...
Jan 15, 2019 07:30 am ET
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced the appointment of Terry Coelho as Chief Financial...
Dec 13, 2018 07:00 am ET
Antares Pharma Announces the Appointment of Peter S. Greenleaf to Company’s Board of Directors
Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Peter S. Greenleaf to the Company’s Board of Directors.  Mr. Greenleaf has over 20 years of biopharmaceutical experience, and currently serves as the Chief Executive Officer of...
Dec 11, 2018 08:30 am ET
Avadel Pharmaceuticals Appoints Kevin Kotler to the Company’s Board of Directors
Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today announced that Kevin Kotler, the founder and Portfolio Manager of Broadfin...
Nov 12, 2018 09:00 am ET
Consolidated Research: 2018 Summary Expectations for Murphy Oil, REGENXBIO, CRA International,Inc, Carriage Services, CONMED, and BioDelivery Sciences International — Fundamental Analysis, Key Perform
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Murphy Oil Corporation (NYSE:MUR), REGENXBIO Inc. (NASDAQ:RGNX), CRA...
Nov 08, 2018 04:05 pm ET
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today reported record financial results for the third quarter ending...
Nov 01, 2018 04:10 pm ET
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that a leading U.S. pharmacy benefit manager has added...
Oct 29, 2018 08:30 am ET
BioDelivery Sciences Announces Changes to its Executive Leadership Team
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain, appointed James Vollins as General Counsel and member of its Executive...
Oct 23, 2018 08:00 am ET
BioDelivery Sciences to Report Third Quarter 2018 Financial Results on November 8, 2018
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that it will report its third quarter 2018 financial...
Oct 17, 2018 08:55 am ET
New Research: Key Drivers of Growth for IDT, Live Nation Entertainment, BioDelivery Sciences International, Spero Therapeutics, Aimmune Therapeutics, and Cars — Factors of Influence, Major Initiatives
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of IDT Corporation (NYSE:IDT), Live Nation Entertainment, Inc. (NYSE:LYV),...
Sep 25, 2018 08:00 am ET
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer will present at...
Sep 13, 2018 07:30 am ET
BioDelivery Sciences to Host Institutional Investor and Analyst Day on Friday, October 5, 2018
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that the company will host an Institutional Investor and...
Sep 10, 2018 08:00 am ET
BioDelivery Sciences to Present at the 2018 Janney Montgomery Scott Healthcare Conference
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial stage specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer, will present at the...
Aug 23, 2018 08:10 am ET
Factors of Influence in 2018, Key Indicators and Opportunity within Aurora Cannabis, Canopy Growth, MobileIron, Sangamo Therapeutics, BioDelivery Sciences International, and First Solar — New Research
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Aurora Cannabis Inc. (OTC:ACBFF), Canopy Growth Corporation (NYSE:CGC),...
Aug 21, 2018 08:00 am ET
BioDelivery Sciences to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain, today announced that Herm Cukier, Chief Executive Officer will present at the Rodman ...
Aug 15, 2018 09:26 am ET
BioDelivery Sciences Secures Significant Expanded Preferred Coverage for BELBUCA®
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial specialty pharmaceutical company dedicated to patients living with chronic pain today announced that a leading U.S. pharmacy benefit manager has added BELBUCA®...
Aug 09, 2018 04:05 pm ET
BioDelivery Sciences Reports Strong Second Quarter 2018 Financial Results
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a leading specialty pharmaceutical company focused on patients living with chronic pain, today reported financial results for the second quarter ending June 30, 2018, as well as the following...
Aug 07, 2018 08:30 am ET
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf
EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment...
Jul 30, 2018 07:55 am ET
BioDelivery Sciences Appoints Thomas Smith, MD as Chief Medical Officer Further Expanding Company’s Expertise in Field of Pain Management
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a leading commercial based specialty pharmaceutical company focused on patients living with chronic pain has appointed Thomas B. Smith, MD, FAAFP, as Chief Medical Officer and member of the...
Jul 24, 2018 04:30 pm ET
BioDelivery Sciences to Report Second-Quarter 2018 Financial Results on August 9, 2018
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it will report its second quarter 2018 financial results after the close of the U.S. Financial markets on Thursday, August 9, 2018. The company will host a conference call...
Jun 15, 2018 07:45 am ET
Analysis: Positioning to Benefit within Uranium Energy, Bellicum Pharmaceuticals, Tutor Perini, Maiden, Hill-Rom, and BioDelivery Sciences International — Research Highlights Growth, Revenue, and Cons
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Uranium Energy Corp. (NYSE:UEC), Bellicum Pharmaceuticals, Inc....
Jun 01, 2018 08:00 am ET
BioDelivery Sciences to Present at the William Blair 2018 Growth Stock Conference
BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a leading specialty pharmaceutical company in the field of pain management and addiction medicine, announced today that both Herm Cukier, Chief Executive Officer and Scott Plesha, President...
May 23, 2018 08:00 am ET
BioDelivery Sciences to Present at the Jefferies 2018 Global Healthcare Conference
BioDelivery Sciences International, Inc., (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Herm Cukier, Chief Executive Officer, and Scott Plesha, President will present...
May 22, 2018 08:29 am ET
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering of newly designated Series B Non-Voting Convertible Preferred Stock.  The offering closed on May...
May 17, 2018 08:01 am ET
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to...
May 17, 2018 08:01 am ET
BioDelivery Sciences Announces Pricing of $50 Million Equity Financing
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into definitive agreements with existing institutional and other accredited investors to purchase an aggregate of approximately $50 million worth of BDSI’s...
May 10, 2018 04:01 pm ET
BioDelivery Sciences Reports Positive First Quarter 2018 Financial Results and Provides Corporate Update
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today reported financial results for the first quarter ended March 31, 2018 and provided an update on recent business highlights. “BELBUCA® prescription growth this quarter was strong,...
May 07, 2018 09:00 am ET
BioDelivery Sciences Appoints Herm Cukier as Chief Executive Officer
BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, announced today that Herm Cukier has been appointed Chief Executive Officer and a member of the Board...
May 03, 2018 09:01 am ET
BioDelivery Sciences Confirms Receipt of Notice of Intent to Nominate Directors by Broadfin Capital
BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today issued the following statement with respect to its receipt of a notice from Broadfin Capital, LLC (together with its affiliates, “Broadfin”) of nominations of director candidates for...
Apr 30, 2018 07:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2018 Financial Results on Thursday, May 10
RALEIGH, N.C., April 30, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report its financial results for the first...
Apr 19, 2018 08:25 am ET
Recent Analysis Shows J.Jill, BankUnited, Toronto Dominion Bank, Adamis Pharmaceuticals, BioDelivery Sciences International, and First Solar Market Influences — Renewed Outlook, Key Drivers of Growth
NEW YORK, April 19, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of J.Jill, Inc. (NYSE:JILL), BankUnited, Inc. (NYSE:BKU),...
Mar 15, 2018 04:37 pm ET
CORRECTING and REPLACING -- BioDelivery Sciences Reports Fourth Quarter and Full-Year 2017 Financial Results and Provides Corporate Update
In a release issued under the same headline earlier today by BioDelivery Sciences International, Inc. (NASDAQ:BDSI), please note that in the second bullet of the Corporate section, the end date of the non-exclusive license for BUNAVAIL is July 23, 2028, not...
Mar 14, 2018 07:00 am ET
BioDelivery Sciences to Present at the Oppenheimer 28th Annual Healthcare Conference
RALEIGH, N.C., March 14, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President of BDSI, will present at the...
Mar 07, 2018 07:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2017 Financial Results on Thursday, March 15
RALEIGH, N.C., March 07, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it will report its financial results for the fourth...
Mar 05, 2018 07:00 am ET
BioDelivery Sciences to Present at the 30th Annual ROTH Conference
RALEIGH, N.C., March 05, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Scott Plesha, President of BDSI, will present at the...
Feb 09, 2018 07:50 am ET
Report: Exploring Fundamental Drivers Behind Great Lakes Dredge & Dock, American Midstream Partners, LP, BioDelivery Sciences International, Viking Therapeutics, Pattern Energy Group, and Computer Pro
NEW YORK, Feb. 09, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Great Lakes Dredge & Dock Corporation...
Feb 06, 2018 07:00 am ET
BioDelivery Sciences Announces BELBUCA® Patent Litigation Settlement Agreement with Teva
RALEIGH, N.C., Feb. 06, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI’s previously...
Jan 30, 2018 08:00 am ET
Jan 04, 2018 08:00 am ET
Savara Announces Appointment of Peter Ginsberg as Vice President of Business Development
Savara, Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that Peter Ginsberg has joined the company as Vice President of Business Development. An accomplished orphan lung disease business development and investment executive, Mr....
Dec 20, 2017 08:45 am ET
BioDelivery Sciences Appoints Scott Plesha to President
RALEIGH, N.C., Dec. 20, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced the appointment of Scott Plesha, currently Senior Vice President of Sales and Marketing at BDSI, to the role of President, effective January 2, 2018. ...
Dec 18, 2017 07:00 am ET
BioDelivery Sciences Announces Notice of Allowance of Patent Strengthening Patent Protection on BELBUCA® to 2032
RALEIGH, N.C., Dec. 18, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance of BDSI’s patent application, that once formally granted, will be Orange...
Dec 14, 2017 04:31 pm ET
BioDelivery Sciences Reacquires ONSOLIS® from Collegium Pharmaceutical
RALEIGH, N.C., Dec. 14, 2017 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) announced that it has received the required 90-day notice from Collegium Pharmaceutical, Inc. regarding termination of the license and development agreement for ONSOLIS® (fentanyl buccal...
Nov 27, 2017 06:00 am ET
BioDelivery Sciences Announces Ohio Workers Compensation Adding BELBUCA and BUNAVAIL to Formulary
RALEIGH, N.C., Nov. 27, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the Ohio Bureau of Workers Compensation (BWC) has approved a change to its formulary resulting in favorable positioning for both BDSI's products BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII).   BELBUCA will be added to the formulary as a Tier 1 long-acting opioid without restrictions.  BUNAVAIL will be added to the formulary and covered in claims with an allowed condition for opioid use disorder, while Suboxone film, S
Nov 20, 2017 08:15 am ET
Market Trends Toward New Normal in OneMain, Versum Materials, BioDelivery Sciences International, Microsemi, Pattern Energy Group, and Omega Protein — Emerging Consolidated Expectations, Analyst Ratin
NEW YORK, Nov. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of OneMain Holdings, Inc. (NYSE:OMF), Versum Materials...
Nov 16, 2017 07:00 am ET
BioDelivery Sciences to Present at the 29th Annual Piper Jaffray Conference
RALEIGH, N.C., Nov. 16, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer, will present at the 29th Annual Piper Jaffray Conference, taking place November 28-29, 2017 in New York City.
Nov 09, 2017 04:01 pm ET
BioDelivery Sciences Reports Third Quarter 2017 Financial Results and Provides Corporate Update
RALEIGH, N.C., Nov. 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and nine months ended September 30, 2017, and provided an update on recent business highlights and upcoming milestones.
Nov 03, 2017 06:15 pm ET
Stull, Stull & Brody Announces Investigation Relating to Potential Securities Law Violations by BioDelivery Sciences International, Inc. (NASDAQ:BDSI)
NEW YORK, Nov. 3, 2017 /PRNewswire/ -- Stull, Stull & Brody today announces it has commenced an investigation of BioDelivery Sciences International, Inc. ("BioDelivery" or the "Company") (NASDAQ:BDSI) concerning possible violations of federal securities laws.
Nov 02, 2017 11:52 am ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by BioDelivery Sciences International, Inc.
Levi & Korsinsky announces it has commenced an investigation of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) concerning possible breaches of fiduciary duty. To obtain additional information, go to:
Oct 30, 2017 08:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2017 Financial Results on November 9
RALEIGH, N.C., Oct. 30, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its third quarter 2017 financial results and host a conference call and webcast at 4:30 PM Eastern Time on Thursday, November 9, 2017.
Oct 12, 2017 08:00 am ET
BioDelivery Sciences Announces Patent Litigation Settlement Agreement with Teva
RALEIGH, N.C., Oct. 12, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, today announced that it has entered into a Settlement Agreement with Teva Pharmaceuticals USA, Inc., Actavis Laboratories UT, Inc. and Teva Pharmaceuticals Industries, Ltd. (Teva) that resolves BDSI's previously reported BUNAVAIL® patent litigation against Teva pending in the United States District Court for the District of Delaware. 
Oct 06, 2017 08:00 am ET
BioDelivery Sciences Participates in U.S. Department of Health and Human Services Round Table Discussion on Pain Management and Opioid Dependence
RALEIGH, N.C., Oct. 6, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) participated in a round table meeting convened this week in Washington, D.C. by the U.S. Department of Health and Human Services (HHS) to discuss efforts to advance pain management therapies and the treatment of opioid dependence as well as advancing alternative therapies. BDSI was represented by its Vice Chairman, President and Chief Executive Officer, Dr. Mark A. Sirgo, who discussed BDSI's work to develop novel products, such as buprenorphine, for the treatment of chronic pain and opioid de
Sep 19, 2017 08:00 am ET
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2017 Healthcare Conference
RALEIGH, N.C., Sept. 19, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer, will present at two upcoming healthcare conferences.
Sep 12, 2017 09:00 am ET
BioDelivery Sciences Announces Granting of Market Authorization Transfer by Health Canada for BELBUCA® and Associated Milestone Payment
RALEIGH, N.C., Sept. 12, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that Health Canada has granted market authorization to formally transfer the Drug Identification Number (DIN) ownership of BELBUCA® (buprenorphine) buccal film in Canada to BDSI's commercial partner, Purdue Pharma (Canada).  As previously announced, this approval triggers a milestone payment to BDSI.
Sep 07, 2017 09:00 am ET
BioDelivery Sciences Presents Data on BELBUCA® (buprenorphine) Buccal Film at the PAINWeek 2017 Conference
RALEIGH, N.C., Sept. 7, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) presented three posters including results from an analysis of data which evaluated the reported adverse respiratory effects of BELBUCA® (buprenorphine) buccal film and a separate analysis of potential health economic benefits of buprenorphine at the PAINWeek 2017 Conference being held this week in Las Vegas, NV.
Aug 24, 2017 08:30 am ET
BioDelivery Sciences to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
RALEIGH, N.C., Aug. 24, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, Vice Chairman, President and Chief Executive Officer, will present at the Rodman & Renshaw 19th Annual Global Investment Conference.  The presentation, which will be webcast, is scheduled for Tuesday, September 12, 2017 at 11:40 AM Eastern Time and will be held at the Lotte New York Palace in New York City.
Aug 23, 2017 08:30 am ET
BioDelivery Sciences President and Chief Executive Officer Dr. Mark A. Sirgo to Retire at Year-End While Continuing as Vice Chairman
RALEIGH, N.C., Aug. 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that at the end of 2017, Dr. Mark A. Sirgo will retire as BDSI's President and Chief Executive Officer, roles which he has held since 2005.  Dr. Sirgo will remain as Vice Chairman of the Board of Directors where he will continue to provide leadership and guidance to BDSI.  Dr. Sirgo and the Board will work together during the coming months to determine his successor.
Aug 17, 2017 08:00 am ET
BioDelivery Sciences to Present Three Posters on BELBUCA® and BUNAVAIL® at PAINWeek 2017
RALEIGH, N.C., Aug. 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present three posters reviewing the potential impacts of BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) on important issues pertinent to the opioid epidemic, such as safety and diversion, at the PAINWeek 2017 meeting in Las Vegas, NV on September 5 - 9, 2017.
Aug 09, 2017 05:01 pm ET
BioDelivery Sciences Reports Second Quarter 2017 Financial Results and Provides Corporate Update
RALEIGH, N.C., Aug. 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the three and six months ended June 30, 2017, and provided an update on recent business highlights and upcoming milestones.
Jul 31, 2017 08:00 am ET
BioDelivery Sciences Publishes Shareholder Letter with Mid-Year Corporate Update
RALEIGH, N.C., July 31, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, announced today that it has published a letter to its shareholders providing a mid-year corporate update, including recent accomplishments and anticipated upcoming milestones. 
Jul 28, 2017 10:27 am ET
/C O R R E C T I O N -- BioDelivery Sciences International, Inc./
In the news release, BioDelivery Sciences to Host Conference Call and Webcast Reporting, issued 28-Jul-2017 by BioDelivery Sciences International, Inc. over PR Newswire, we are advised by the company that the headline was missing the date of the conference call as incorrectly transmitted by PR Newswire. The complete, corrected release follows:
Jul 12, 2017 08:30 am ET
BioDelivery Sciences Signs Exclusive Agreement With Purdue Pharma (Canada) For The Licensing And Distribution Rights Of BELBUCA® In Canada
RALEIGH, N.C. and PICKERING, Ontario, July 12, 2017 /PRNewswire/ -- Today, BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company with a focus in pain management and addiction medicine, and Purdue Pharma (Canada) announce that they have signed an exclusive agreement for the licensing, distribution, marketing and sale of BELBUCA® (buprenorphine buccal film) in Canada.
Jun 23, 2017 08:00 am ET
BioDelivery Sciences Announces Health Canada Approval of BELBUCA®
RALEIGH, N.C., June 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Health Canada, the regulatory authority in Canada, has issued a Notice of Compliance (NOC) approving BELBUCA® (buprenorphine hydrochloride buccal film) for the management of pain severe enough to require daily, continuous, long-term treatment and is opioid responsive and for which alternative options are inadequate.  BDSI plans to commercialize BELBUCA in Canada through a partner, and the approval is an important step in the partnering process.  BELBUCA is expected to be launch
Jun 21, 2017 09:48 am ET
BioDelivery Sciences Announces Agreement with CVS/Caremark for BELBUCA® and BUNAVAIL® Through 2020
RALEIGH, N.C., June 21, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has signed an agreement with CVS/Caremark extending access to both BELBUCA® (buprenorphine) buccal film (CIII) and BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) through 2020.  The agreement is important as CVS/Caremark represents a significant portion of the covered lives in the United States. 
Jun 01, 2017 08:49 am ET
BioDelivery Sciences to Present at the Jefferies 2017 Healthcare Conference and the William Blair 2017 Growth Stock Conference
RALEIGH, N.C., June 1, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at two upcoming healthcare conferences.
May 15, 2017 08:17 pm ET
/C O R R E C T I O N -- BioDelivery Sciences International, Inc./
In the news release, BioDelivery Sciences Reports First Quarter 2017 Financial Results and Provides Corporate Update, issued 15-May-2017 by BioDelivery Sciences International, Inc. over PR Newswire, we are advised by the company that the Basic income (loss) per share and Diluted income (loss) per share figures for the Three Months Ended March 31, 2017 have been updated. The complete, corrected release follows:
May 09, 2017 10:23 am ET
BioDelivery Sciences to Host Conference Call and Webcast Reporting First Quarter 2017 Financial Results on Monday, May 15
RALEIGH, N.C., May 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its first quarter 2017 financial results and host a conference call and webcast at 4:30 PM Eastern Time on Monday, May 15, 2017.
May 02, 2017 08:00 am ET
BioDelivery Sciences Announces the Approval of BUNAVAIL® for Induction of Buprenorphine Treatment for Opioid Dependence
RALEIGH, N.C., May 2, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the U.S. Food and Drug Administration (FDA) has approved a Supplemental New Drug Application (sNDA) for BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) revising the indication to include the use of BUNAVAIL for the initiation of buprenorphine treatment for opioid dependence.
Apr 26, 2017 08:00 am ET
BioDelivery Sciences to Present at the Deutsche Bank 42nd Annual Health Care Conference
RALEIGH, N.C., April 26, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Deutsche Bank 42nd Annual Health Care Conference. The presentation, which will be webcast, is scheduled for Wednesday, May 3, 2017 at 11:20 AM Eastern Time and will be held at The Intercontinental Hotel in Boston, Massachusetts.
Mar 31, 2017 08:00 am ET
BioDelivery Sciences Announces the Granting of Two New Patents to be Listed in FDA's Orange Book Further Extending and Strengthening Patent Protection on BELBUCA®, BUNAVAIL® and ONSOLIS®
RALEIGH, N.C., March 31, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that two important new patents were granted extending patent protection around all three of its FDA approved products, BELBUCA® (buprenorphine) buccal film, BUNAVAIL® (buprenorphine and naloxone) buccal film, and ONSOLIS® (fentanyl buccal soluble film), further strengthening BDSI's overall intellectual property position.
Mar 17, 2017 07:30 am ET
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
RALEIGH, N.C., March 17, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (BDSI) today reported financial results for the fourth quarter and full year ended December 31, 2016, and provided an update on recent business highlights and upcoming milestones.
Mar 16, 2017 10:24 am ET
BioDelivery Sciences Announces Three Data Presentations on BELBUCA® at the American Academy of Pain Medicine 33rd Annual Meeting
RALEIGH, N.C., March 16, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced three data presentations from research surrounding BELBUCA® (buprenorphine) buccal film (CIII) at the American Academy of Pain Medicine (AAPM) 33rd Annual Meeting in Orlando, Florida on March 16-19.
Mar 09, 2017 07:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast Reporting Fourth Quarter and Full-Year 2016 Financial Results on Friday, March 17
RALEIGH, N.C., March 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its fourth quarter and full-year 2016 financial results and host a conference call and webcast at 8:00 AM Eastern Time on Friday, March 17, 2017.
Mar 08, 2017 07:00 am ET
BioDelivery Sciences to Present at the 29th Annual ROTH Conference
RALEIGH, N.C., March 8, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 29th Annual ROTH Conference. The presentation, which will be webcast, is scheduled for Monday, March 13, 2017 at 9:00 AM Pacific Time (12:00 PM Eastern Time) and will be held at The Ritz Carlton Laguna Niguel in Dana Point, California. The conference is one of the largest of its kind in the U.S. with close to 500 participating companies and over 4,000 attendees last year.
Feb 23, 2017 07:30 am ET
BioDelivery Sciences Secures Debt Financing with CRG
RALEIGH, N.C., Feb. 23, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced today that it has entered into a senior credit facility with affiliates of CRG LP, a healthcare-focused investment firm, to retire its existing credit facility and provide additional working capital for the company.
Jan 26, 2017 03:24 pm ET
BioDelivery Sciences to Hold Analyst and Investor Day to Discuss BELBUCA® Commercialization Plans on February 1st in New York City
RALEIGH, N.C., Jan. 26, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will host an event for analysts and investors from 12:00 PM – 2:30 PM Eastern Time on Wednesday, February 1st, 2017, in New York City, to discuss BELBUCA® (buprenorphine) buccal film (CIII) and plans for the commercialization of BELBUCA, as well as BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII).  The event follows the closing of BDSI's previously announced agreement with Endo Pharmaceuticals, Inc. (Endo), which transferred the worldwide rights to BELBUCA back to BDSI.
Jan 13, 2017 03:39 pm ET
MonoSol Rx Files Patent Infringement Suit against BioDelivery Sciences International (BDSI)
WARREN, N.J., Jan. 13, 2017 (GLOBE NEWSWIRE) -- MonoSol Rx, a specialty pharmaceutical company utilizing its PharmFilm® drug delivery technology to improve patient outcomes and to address unmet needs, today filed a patent infringement case against BioDelivery Sciences International, Inc. (Nasdaq:BDSI) (“BDSI”) for infringement of U.S. Patent No. 8,765,167 (the ‘167 patent), which is entitled “Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions.”  The ‘167 patent has a priority date as far back as 2001, as well as additional priority in 2005.  The complaint ...
Jan 09, 2017 09:45 am ET
BioDelivery Sciences Closes Transaction to Reacquire License to BELBUCA® from Endo Pharmaceuticals
RALEIGH, N.C., Jan. 9, 2017 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the closing of its previously announced agreement with Endo Pharmaceuticals, Inc. (Endo) terminating Endo's licensing of rights for BELBUCA® (buprenorphine) buccal film (CIII).  This transaction follows a strategic decision announced by Endo in December regarding its U.S. branded pain business.  
Dec 14, 2016 07:00 am ET
BioDelivery Sciences Announces the Hiring of Peter Ginsberg as Vice President of Business Development
RALEIGH, N.C., Dec. 14, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Peter Ginsberg has joined the company as Vice President of Business Development.  Mr. Ginsberg joins BDSI with over 25 years of business development and other closely related experience.
Dec 13, 2016 06:55 am ET
BioDelivery Sciences Announces Clonidine Topical Gel for Painful Diabetic Neuropathy Phase 2b Trial Fails to Meet its Primary Efficacy Endpoint
RALEIGH, N.C., Dec. 13, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that its Phase 2b clinical study assessing the efficacy and safety of Clonidine Topical Gel for the management of painful diabetic neuropathy failed to show a statistically significant difference in pain relief between Clonidine Topical Gel and placebo.  As a result, BDSI is discontinuing further development of the product at this time.
Dec 08, 2016 06:00 am ET
BioDelivery Sciences Reacquires License to BELBUCA™ from Endo Pharmaceuticals
RALEIGH, N.C., Dec. 8, 2016 /PRNewswire/ --BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has entered into an agreement with Endo Pharmaceuticals, Inc. (Endo) terminating their licensing of rights for BELBUCA™ (buprenorphine) buccal film. This transaction follows a strategic decision made by Endo regarding their U.S. branded pain business.  
Nov 23, 2016 07:00 am ET
BioDelivery Sciences to Present at the 28th Annual Piper Jaffray Healthcare Conference
RALEIGH, N.C., Nov. 23, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 28th Annual Piper Jaffray Healthcare Conference. 
Nov 09, 2016 06:00 am ET
BioDelivery Sciences Provides Corporate Update and Reports Third Quarter 2016 Financial Results
RALEIGH, N.C., Nov. 9, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the third quarter ended September 30, 2016, and provided an update on recent business highlights and upcoming milestones.
Nov 08, 2016 07:00 am ET
BioDelivery Sciences to Present at the Stifel 2016 Healthcare Conference
RALEIGH, N.C., Nov. 8, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Stifel 2016 Healthcare Conference.  The presentation, which will be webcast, is scheduled for Tuesday, November 15, at 1:30 PM Eastern Time at the Lotte New York Palace Hotel in New York City.
Nov 01, 2016 08:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast Reporting Third Quarter 2016 Financial Results on Wednesday, November 9
RALEIGH, N.C., Nov. 1, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host conference call and webcast to report its financial results for the third quarter ended September 30, 2016, on Wednesday, November 9, 2016 before the market open and host a conference call and webcast at 8:00 am Eastern Time.
Oct 24, 2016 08:00 am ET
BioDelivery Sciences Announces Preferred Formulary Status for BUNAVAIL on Texas Medicaid
RALEIGH, N.C., Oct. 24, 2016  /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the addition of BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) as a preferred drug to the Texas Medicaid formulary from its previous non-formulary status.  Suboxone film will share preferred status with BUNAVAIL.  The formulary change goes into effect on January 1, 2017.
Oct 05, 2016 08:00 am ET
BioDelivery Sciences Announces Additions to its Board of Directors
RALEIGH, N.C., Oct. 5, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced additions to its Board of Directors.  Timothy C. Tyson will join the BDSI Board of Directors as an independent member, and Dr. Mark A. Sirgo, BDSI's President and Chief Executive Officer and board member, will, in addition to his current positions, assume the role of Vice Chairman.  Both changes are effective immediately and help to further strengthen BDSI's existing board-level leadership. 
Sep 30, 2016 08:00 am ET
BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule
RALEIGH, N.C., Sept. 30, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) reported that according to the Substance Abuse and Mental Health Services Administration (SAMHSA), 1,665 clinicians have applied for and were granted waivers to prescribe buprenorphine for the treatment of opioid dependence at the increased limit of 275 from the previous 100.
Sep 21, 2016 08:00 am ET
BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference
RALEIGH, N.C., Sept. 21, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Ladenburg Thalmann 2016 Healthcare Conference.  The presentation, which will be webcast, is scheduled for Tuesday, September 27, at 8:30 AM Eastern Time at the Sofitel New York in New York City.
Sep 19, 2016 08:00 am ET
BioDelivery Sciences Announces Three New Managed Care Agreements; Further Enhancing Access to BUNAVAIL
RALEIGH, N.C., Sept. 19, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that the company has secured three new managed care contracts for BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) in plans where BUNAVAIL was previously non-formulary or in a non-preferred position. 
Sep 06, 2016 08:00 am ET
BioDelivery Sciences to Present at the Rodman & Renshaw 18th Annual Global Investment Conference and the 7th Annual Credit Suisse Small and Mid Cap Conference
RALEIGH, N.C., Sept. 6, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at two upcoming healthcare conferences:
Aug 09, 2016 07:00 am ET
BioDelivery Sciences Provides Corporate Update and Reports Second Quarter 2016 Financial Results
RALEIGH, N.C., Aug. 9, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) today reported financial results for the second quarter ended June 30, 2016, and provided an update on recent business highlights and upcoming milestones.
Aug 04, 2016 08:00 am ET
BioDelivery Sciences Announces Randomization Target Reached in Clinical Trial of Clonidine Topical Gel for the Treatment of Painful Diabetic Neuropathy
RALEIGH, N.C., Aug. 4, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it has reached its target number of subjects to be randomized in its multi-center, double-blind, placebo-controlled Phase 2b study assessing the efficacy and safety of Clonidine Topical Gel in the treatment of pain associated with painful diabetic neuropathy.  Based on the timing of randomization of the last patient, BDSI now expects topline results of the study will be available by the end of this year, which puts it six to eight weeks ahead of schedule.
Aug 01, 2016 08:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast of Second Quarter 2016 Results on Tuesday, August 9
RALEIGH, N.C., Aug. 1, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host a conference call and webcast on Tuesday, August 9, at 8:00 A.M. Eastern time.  During the call, management will review BDSI's second quarter 2016 financial results and provide a business update. 
Jul 18, 2016 07:47 am ET
Biomerica Adds Dr. Mark Sirgo to Board of Directors
Biomerica Inc. (OTCQB: BMRA) today announced that it has added Dr. Mark A. Sirgo to its Board of Directors, expanding the Board to six members which includes four outside members.Dr. Mark A. Sirgo served on the Board of Directors and as Chairman of...
Jul 11, 2016 05:01 pm ET
BioDelivery Sciences Announces the Securing of Preferred Formulary Status for BUNAVAIL on a Significant Managed Care Plan
RALEIGH, N.C., July 11, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced it has signed an agreement with a significant managed care provider providing preferred access to BUNAVAIL® (buprenorphine and naloxone) buccal film (CIII) for the maintenance treatment of opioid dependence. 
Jul 06, 2016 08:00 am ET
BioDelivery Sciences to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
RALEIGH, N.C., July 6, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference.  The presentation, which will be webcast, is scheduled for Tuesday, July 12, 2016, at 8:30 AM Eastern Time at the Le Parker Meridien Hotel in New York City.
Jun 08, 2016 08:00 am ET
BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference
RALEIGH, N.C., June 8, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) will present at the William Blair Annual Growth Stock Conference.  The presentation, which will be webcast, is scheduled for Wednesday, June 15, 2016, at 11:40 AM Eastern Time at the Four Seasons Hotel in Chicago.
Jun 06, 2016 08:00 am ET
BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids
RALEIGH, N.C., June 6, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the presentation of data today at the 5th International Conference on Opioids (ICOO 2016), which takes place June 5-7, 2016 in Boston, Massachusetts.  The poster is being presented by Dr. Richard Soper, Chief, Addiction Medicine & Chair, Board of Directors, Center for Behavioral Wellness, Nashville, Tennessee, who is lead author.
Jun 03, 2016 09:00 am ET
New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain
Findings also show sustained pain relief with BELBUCA™ treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
Jun 03, 2016 09:00 am ET
New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain
Findings also show sustained pain relief with BELBUCA™ treatment for up to 48 weeks among chronic pain sufferers who require around-the-clock pain relief
Jun 02, 2016 08:00 am ET
BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference
RALEIGH, N.C., June 2, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference.  The presentation, which will be webcast, is scheduled for Wednesday, June 8, 2016, at 11:00 AM Eastern Time at the Grand Hyatt in New York City.
May 11, 2016 05:05 pm ET
BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.
RALEIGH, N.C., May 11, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) and Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced the signing of a licensing agreement under which BDSI is granting the exclusive rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) in the U.S. to Collegium.
May 11, 2016 04:05 pm ET
Collegium Licenses the U.S. rights to ONSOLIS® from BioDelivery Sciences
CANTON, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced today the licensing of the U.S. rights to develop and commercialize ONSOLIS® (fentanyl buccal soluble film) from BioDelivery Sciences International, Inc. (Nasdaq:BDSI). Collegium expects to launch the product in mid-2017....
May 10, 2016 08:00 am ET
May 03, 2016 08:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast of First Quarter 2016 Results on Tuesday, May 10
RALEIGH, N.C., May 3, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will host a conference call and webcast on Tuesday, May 10, at 8:00 A.M. Eastern time.  During the call, management will review BDSI's first quarter 2016 financial results and provide a business update. 
Apr 29, 2016 08:00 am ET
BioDelivery Sciences Announces Acceptance of an Abstract to the International Conference on Opioids on the Impact of a State Formulary Conversion to BUNAVAIL
RALEIGH, N.C., April 29, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the acceptance of an abstract for presentation at the International Conference on Opioids, which takes place June 5-7, 2016 in Boston, Massachusetts.  The abstract entitled, Reduced Buprenorphine/Naloxone Prescriptions Dispensed in a State Medicaid Population Following Formulary Conversion from Suboxone to Bunavail: Implications for Potential Diversion, has been accepted for a poster presentation to take place on Monday, June 6.  Dr. Richard Soper, Chief, Addiction Medicine & C
Mar 14, 2016 08:00 am ET
BioDelivery Sciences to Present Today at the 28th Annual ROTH Conference
RALEIGH, N.C., March 14, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the 28th Annual ROTH Conference.  The conference, which will be webcast, is scheduled for today, Monday, March 14, 2016, at 9:00 – 9:30 AM Pacific Time (12:00 – 12:30 PM Eastern Time).
Mar 10, 2016 04:01 pm ET
BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
RALEIGH, N.C., March 10, 2016 /PRNewswire/ --  BioDelivery Sciences International, Inc. (NASDAQ: BDSI) reported financial results for the fourth quarter and full-year ended December 31, 2015, and reviewed its most significant recent accomplishments and upcoming milestones.
Mar 04, 2016 07:00 am ET
BioDelivery Sciences to Present at the Cowen and Company 36th Annual Healthcare Conference and the 28th Annual ROTH Conference
RALEIGH, N.C., March 4, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at two upcoming healthcare conferences:
Mar 03, 2016 07:00 am ET
BioDelivery Sciences to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Results on Thursday, March 10
RALEIGH, N.C., March 3, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced that it will report its fourth quarter and full-year 2015 financial results and host a conference call and webcast at 5:00 pm Eastern Time on Thursday, March 10, 2016.
Feb 22, 2016 07:45 am ET
BioDelivery Sciences Announces the Launch of BELBUCA™ (Buprenorphine) Buccal Film by Endo Pharmaceuticals for Chronic Pain Management
RALEIGH, N.C., Feb. 22, 2016 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI) announced the commercial availability of BEBUCA™ (buprenorphine) buccal film for use in patients with chronic pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. BELBUCA™, distributed and promoted by Endo Pharmaceuticals, is now available nationwide.
Feb 22, 2016 07:30 am ET
Endo Announces Launch Of BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain Management
New opioid analgesic with novel drug delivery now available by prescription in U.S.
Feb 22, 2016 07:30 am ET
Endo Announces Launch Of BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain Management
New opioid analgesic with novel drug delivery now available by prescription in U.S.

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.